(19) World Intellectual Property Organization International Bureau



I ALDIA BINDADA NI KATUNA KATA BAHA BAHA BAHA BAHA KAN KATA BUBA BAHA KAN BAHA BAHA MALA BAHAR HAN KAN KATA KA

(43) International Publication Date 10 March 2005 (10.03.2005)

PCT

(10) International Publication Number WO 2005/020892 A2

(51) International Patent Classification7:

A61K

(21) International Application Number:

PCT/US2004/025512

(22) International Filing Date: 5 August 2004 (05.08.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/493,447	8 August 2003 (08.08.2003)	US
60/499,637	2 September 2003 (02.09.2003)	US
60/511,746	15 October 2003 (15.10.2003)	US
60/562,496	14 April 2004 (14.04.2004)	US
60/562,384	14 April 2004 (14.04.2004)	US

- (71) Applicant (for all designated States except US): VDF FU-TURECEUTICALS [US/US]; 300 West 6th Street, Momence, Illinois 60954-0009 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MILJKOVIC, Dusan [YU/US]; 4655 Ramsay Avenue, San Diego, California 92122 (US). HRANISAVLJEVIC, Jovan [YU/YU]; 109 Gosboodara Vucica, YU-11000 Belgrade (YU). PIETRZKOWSKI, Zbigniew [PL/US]; 5370 Toscana Way, H-411, San Diego, California 92122 (US). HUNTER, John [US/US]; 17256 Vollbrecht Drive,

S. Holland, IL 60473 (US). VAN DRUNEN, Jeffrey [US/US]; 15902 Parkside, South Holland, IL 60473 (US).

- (74) Agents: RUTAN & TUCKER et al.; 611 Anton Blvd., 14th Floor, Costa Mesa, CA 92626-1931 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION

(57) Abstract: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia. In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.

